Showing 3021-3030 of 5771 results for "".
- Vabysmo Approved in Europe for Treatment of RVOhttps://modernod.com/news/roches-vabysmo-approved-in-europe-for-treatment-of-rvo/2482379/Roche announced that the European Commission has approved Vabysmo (faricima) for the treatment of visual impairment caused by macular edema secondary to retinal vein occlusion (RVO, branch RVO or central RVO). RVO is the third indication for Vabysmo in the European Union, in addition to wet
- ViaLase Laser Receives CE Mark Approval to Treat Glaucomahttps://modernod.com/news/vialase-laser-receives-ce-mark-approval-to-treat-glaucoma/2482378/ViaLase announced that it has received CE Mark approval in the European Union for the ViaLase laser for the treatment of adult patients with primary open-angle glaucoma. According to the company, the ViaLase laser combines the precision of a femtosecond laser and the accuracy of micron-
- Clearside and Arctic Vision Report Data From Trial of Arcatis to Treat Uveitic Macular Edema in Chinahttps://modernod.com/news/clearside-and-arctic-vision-report-data-from-trial-of-arcatis-to-treat-uveitic-macular-edema-in-china/2482380/Clearside Biomedical announced that its partner, Arctic Vision, reported topline results from its phase 3 clinical trial of Arcatus (ARVN001) for the treatment of uveitic macular edema in China. In addition, Arctic Vision announced that new drug applications for Arcatus have been officially accep
- Spryte Medical Receives Breakthrough Device Designation from FDA for Neuro OCT Technologyhttps://modernod.com/news/spryte-medical-receives-breakthrough-device-designation-from-fda-for-neuro-optical-coherence-tomography-noct-technology/2482373/Spryte Medical announced that its neuro Optical Coherence Tomography (nOCT) technology has been granted Breakthrough Device Designation by the FDA. This recognition underscores the potential of nOCT in neurointervention and cerebrovascular treatment. The FDA’s
- Oertli Receives FDA 510(k) Clearance for Faros Surgical Systemhttps://modernod.com/news/oertli-instrumente-ag-achieves-milestone-with-fda-510k-clearance-for-faros-surgical-system/2482371/Oertli Instrumente announced it has received FDA 510(k) clearance for the Faros anterior cataract surgery system. According to a company news release, the Faros system offers a compact design and rapid operational readiness, requiring minimal space in operating rooms. It
- Osheru Secures $4.7 Million Seed Funding to Advance Ziplyft Device for Blepharoplasty Surgeryhttps://modernod.com/news/osheru-secures-47-million-seed-funding-to-advance-ziplyft-device-for-blepharoplasty-surgery/2482370/Osheru announced the completion of a $4.7 million funding round to accelerate the development and commercialization of its Ziplyft device for blepharoplasty surgery. Blepharoplasty, a procedure aimed at rejuvenating the appearance of the eyelids, remains one of the most sought-afte
- Bausch + Lomb Acquires Diagnostic Company Trukera Medicalhttps://modernod.com/news/bausch-lomb-acquires-diagnostic-company-trukera-medical/2482368/Bausch + Lomb announced it has acquired US-based privately held ophthalmic medical diagnostic company Trukera Medical. Financial terms of the deal were not disclosed. An affiliate of B+L acquired Trukera from its private equity owner, AccelMed Partners, and other shareholders. 
- New Data for Susvimo Demonstrates Sustained Efficacy in DME and DRhttps://modernod.com/news/new-data-for-susvimo-demonstrates-sustained-efficacy-in-dme-and-dr/2482365/Genentech and Roche announced 2-year data from the phase 3 Pagoda and Pavilion studies evaluating Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME) and diabetic retinopathy (DR), respectively. Susvimo, which is being
- Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term DME Studyhttps://modernod.com/news/vabysmo-showed-extended-durability-continued-efficacy-and-a-consistent-safety-profile-in-long-term-dme-study/2482363/At the American Society of Retina Specialists (ASRS) 2024 Annual Meeting in Stockholm, Sweden, Genentech announced new, 4-year data from the RHONE-X extension study. The study met all primary endpoints, showing that Vabysmo (faricimab-svoa) was well tolerated in people with diabetic mac
- EssilorLuxottica Acquires Majority Stake in Heidelberg Engineeringhttps://modernod.com/news/essilorluxottica-acquires-majority-stake-in-heidelberg-engineering/2482362/Optical industry giant EssilorLuxottica announced it has reached a deal to acquire an 80% stake in Germany-based Heidelberg Engineering. Financial terms of the deal were not disclosed. Founded by Dr. Gerhard Zinser and Christoph Schoess in 1990, Heidelberg is a prov